BenevolentAI Overview
Pro stress-test →BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. The company develops its own in-house pipeline of drug candidates across therapeutic areas like immunology, neurology, and oncology, engages in discovery collaborations with major pharmaceutical companies including multi-year agreements with AstraZeneca and Merck KGaA valued at up to $594 million. Its AI platform identified baricitinib as a potential Covid-19 treatment within 48 hours, a drug that went on to save lives globally.
Strategic Profile
Pro stress-test →BenevolentAI is exploring a Software-as-a-Service (SaaS) model, offering its knowledge exploration tools to external partners. The company closed its US office in New York and is focusing its efforts from Cambridge and London to optimise growth opportunities. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, maintaining successful collaborations with AstraZeneca and leading research institutions.
Competitive Landscape
Pro stress-test →BenevolentAI's top competitors include Schrodinger, Recursion Pharmaceuticals and XtalPi. The company differentiates through validated AI platform efficacy, major pharma partnerships, and a maturing drug pipeline. Competitors range from computational chemistry platforms to AI-first biotech companies pursuing similar drug discovery acceleration.
Industry Context
BenevolentAI operates in AI-driven drug discovery platforms.
Key facts
Founded: 2013 · Headquarters: London, UK · Employees: 69 · Revenue: $25.4M